Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

From FTC’s tightened grip to PULSE Coalition: A timeline of the life science M&A landscape

By Brian Buntz | October 5, 2023

FTC-DOJThe biopharma industry is pushing back against increased scrutiny of mergers and acquisitions from the Federal Trade Commission (FTC). More than 30 biopharma companies and industry associations announced the formation of the Partnership for the U.S. Life Science Ecosystem (PULSE) to advocate for the role of M&A activity in the biopharma sector. A M&A landscape timeline below highlights some of the events leading up to the emergence of PULSE.

The creation of PULSE comes in response to more aggressive enforcement against pharma mergers by the FTC under the Biden administration. Most recently, the FTC sued to block Amgen’s acquisition of Horizon Therapeutics, before ultimately settling to allow the deal to proceed with conditions.

Since June 2023, there has been a trend of falling M&A deal volume. Deal size has also dipped in recent months, but rising interest rates are another factor influencing that trend.

PULSE members, including Amgen, AbbVie, Gilead, and Merck, argue that M&A helps advance drug discovery and development.

M&A landscape timeline

  1. March 2021: In light of an uptick in large deals in 2019 and a upwelling of M&A deals in 2021, the FTC under Biden signaled that it would re-evaluate its approach to pharma dealmaking to reflect a ‘tougher’ M&A environment.
  2. January 18, 2022: FTC and DOJ announce plans to modernize federal merger guidelines​.
  3. Early 2023: Revival of biopharma M&A after a cooling period during the pandemic. This revival occurred despite rising capital costs and heightened scrutiny from FTC. Aggregate deal values jumped 133% relative to the first half of 2022, hitting $82 billion, according to IQVIA.
  4. May 16, 2023: FTC sues to block Amgen’s acquisition of Horizon Therapeutics​.
  5. July 19, 2023: Federal antitrust agencies propose updates to U.S. merger guidelines​.
  6. August 10, 2023: FTC and DOJ extend the deadline for public comments on proposed changes to the premerger notification form​.
  7. September 1, 2023: Amgen agrees to settle FTC and state challenges to its Horizon Therapeutics acquisition​.
  8. October 4, 2023: Launch of Partnership for the U.S. Life Science Ecosystem (PULSE)​.

Filed Under: Drug Discovery, Legal precedents and interpretations
Tagged With: AbbVie, advocacy, Amgen, Biden administration, biopharma, deal volume, development, drug discovery, enforcement, Federal Trade Commission, FTC, Gilead, Horizon Therapeutics, interest rates, M&A, Merck, mergers and acquisitions, Partnership for the U.S. Life Science Ecosystem, PULSE, timeline
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE